MA54296A - Procédés de traitement du métabolisme lipidique dérégulé - Google Patents

Procédés de traitement du métabolisme lipidique dérégulé

Info

Publication number
MA54296A
MA54296A MA054296A MA54296A MA54296A MA 54296 A MA54296 A MA 54296A MA 054296 A MA054296 A MA 054296A MA 54296 A MA54296 A MA 54296A MA 54296 A MA54296 A MA 54296A
Authority
MA
Morocco
Prior art keywords
treating
methods
lipid metabolism
disregulated
disregulated lipid
Prior art date
Application number
MA054296A
Other languages
English (en)
Inventor
Giuseppe Astarita
Paolo Gilbert Di
kai lin Lin
Kathryn M Monroe
Alicia A Nugent
Lengerich Bettina Van
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MA54296A publication Critical patent/MA54296A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA054296A 2018-11-26 2019-11-26 Procédés de traitement du métabolisme lipidique dérégulé MA54296A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862771456P 2018-11-26 2018-11-26
US201962817955P 2019-03-13 2019-03-13
US201962890506P 2019-08-22 2019-08-22

Publications (1)

Publication Number Publication Date
MA54296A true MA54296A (fr) 2021-10-06

Family

ID=68988303

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054296A MA54296A (fr) 2018-11-26 2019-11-26 Procédés de traitement du métabolisme lipidique dérégulé

Country Status (7)

Country Link
US (1) US20230132366A9 (fr)
EP (1) EP3887401A2 (fr)
JP (1) JP2022513114A (fr)
CN (1) CN113302206A (fr)
CA (1) CA3120970A1 (fr)
MA (1) MA54296A (fr)
WO (1) WO2020112889A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020508049A (ja) 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 操作されたトランスフェリン受容体結合ポリペプチド
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2021146256A1 (fr) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anticorps anti-trem2 et leurs procédés d'utilisation
BR112022013756A2 (pt) 2020-01-13 2022-10-11 Denali Therapeutics Inc Anticorpos anti-trem2 e métodos de uso dos mesmos
WO2021250428A1 (fr) * 2020-06-11 2021-12-16 Quell Therapeutics Limited Récepteur chimérique de trem2
TW202218683A (zh) * 2020-08-05 2022-05-16 美商維佳神經科學有限公司 使用trem2促效劑治療與群落刺激因子1受體功能障礙相關之疾病
CN115015412B (zh) * 2022-05-26 2024-07-05 江苏独步生物科技有限公司 一种与中枢神经损伤修复相关的分子靶标及其应用
CN117771226B (zh) * 2023-12-28 2024-08-20 山东博森医学工程技术有限公司 一种加快骨关节炎损伤修复的促进剂

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR14523E (fr) 1911-02-06 1911-12-30 Daniel German Caswell Perfectionnements dans les vélocipèdes
US4326055A (en) 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
DE3202100A1 (de) 1982-01-23 1983-08-04 Basf Ag, 6700 Ludwigshafen Substituierte benzoesaeure-4-hydroxyanilide, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
ATE163544T1 (de) 1991-12-18 1998-03-15 Salk Inst For Biological Studi Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen
US5780676A (en) 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
AU675430B2 (en) 1992-04-22 1997-02-06 Ligand Pharmaceuticals Incorporated Compounds having selectivity for retinoid X receptors
US5466861A (en) 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
WO1995004036A1 (fr) 1993-01-11 1995-02-09 Ligand Pharmaceuticals Inc. Composes a activite selective pour les recepteurs du retinoide x, et systeme de modulation des processus utilisant des recepteurs du retinoide x comme mediateurs
PT678086E (pt) 1993-01-11 2000-05-31 Ligand Pharm Inc Compostos com selectividade para receptores de retinoides x
US5399586A (en) 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
WO1994023068A1 (fr) 1993-04-07 1994-10-13 Ligand Pharmaceuticals, Incorporated Procede de triage concernant des agonistes de recepteurs
ATE181052T1 (de) 1994-08-10 1999-06-15 Hoffmann La Roche Retinoesäure x-rezeptor liganden
US6083977A (en) 1994-12-30 2000-07-04 Ligand Pharmaceuticals Incorporated Trienoic retinoid compounds and methods
DE69516903T2 (de) 1994-12-30 2000-10-26 Ligand Pharmaceuticals, Inc. Retinoid trienverbindungen und verfahren
JPH09330101A (ja) 1996-06-13 1997-12-22 Kokusai Chodendo Sangyo Gijutsu Kenkyu Center 制御装置及び方法
IT1286031B1 (it) 1996-10-24 1998-07-07 Enichem Spa Procedimento per la produzione di polimeri vinilaromatici ad elevato grado di sindiotassia
US6969711B2 (en) 1997-05-26 2005-11-29 Kowa Company, Ltd. Cyclic diamine compounds and medicine containing the same
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US20030086923A1 (en) 1999-12-13 2003-05-08 Sparrow Carl P. Method for the prevention and/or treatment of atherosclerosis
CA2392568A1 (fr) 1999-12-13 2001-06-14 Merck & Co., Inc. Procede de prevention et/ou de traitement de l'atherosclerose
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1463726A2 (fr) 2001-12-21 2004-10-06 Pharmacia Corporation Modulateurs du recepteur x du foie de thioether aromatique
WO2003059884A1 (fr) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulateurs de lxr
EP1480689A1 (fr) 2002-02-28 2004-12-01 Eli Lilly And Company Procede servant a traiter l'atherosclerose et l'hypercholesterolemie
US6900244B2 (en) 2002-05-24 2005-05-31 Pharmacia Corporation Anilino liver X-receptor modulators
BR0311282A (pt) 2002-05-24 2005-04-19 Pharmacia Corp Moduladores sulfona de receptor-x do fìgado
BR0314390A (pt) 2002-09-17 2005-07-19 Pharmacia Corp Moduladores aromáticos dos receptores hepáticos x
US20050036992A1 (en) 2002-12-23 2005-02-17 Irm Llc Novel use of liver X receptor agonists
US20050009837A1 (en) 2003-05-20 2005-01-13 City Of Hope Modulators of lipid metabolism and methods of use
JP2005128010A (ja) * 2003-10-03 2005-05-19 Takeda Chem Ind Ltd インスリン抵抗性改善剤のスクリーニング方法
BRPI0417543A (pt) 2003-12-12 2007-03-27 Wyeth Corp quinolinas úteis no tratamento de doença cardiovascular
CN101213194A (zh) 2004-08-03 2008-07-02 惠氏公司 可用于治疗心血管疾病的吲唑化合物
AU2007297721A1 (en) 2006-09-19 2008-03-27 Wyeth Use of LXR agonists for the treatment of osteoarthritis
US9149492B2 (en) 2008-10-08 2015-10-06 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of alzheimer's disease
AU2010209273A1 (en) * 2009-01-28 2011-09-01 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
JP5719340B2 (ja) 2009-03-20 2015-05-20 レティーナ インプラント アーゲー 能動型網膜インプラント
WO2013056232A2 (fr) 2011-10-13 2013-04-18 Case Western Reserve University Composés agonistes de rxr et procédés associés
AU2012352149B2 (en) 2011-12-13 2017-06-01 Io Therapeutics, Inc. Autoimmune disorder treatment using RXR agonists
WO2015038585A1 (fr) 2013-09-11 2015-03-19 Trustees Of Dartmouth College Méthode permettant d'inhiber de manière sélective acat1 dans le traitement de la maladie d'alzheimer
WO2015061686A2 (fr) 2013-10-25 2015-04-30 St. Jude Children's Research Hospital, Inc. Agonistes du récepteur des rétinoïdes x type gamma et antagonistes du récepteur des rétinoïdes x type alpha utilisés pour le traitement du cancer
WO2015184105A1 (fr) 2014-05-29 2015-12-03 Trustees Of Dartmouth College Procédé permettant d'inhiber de manière sélective l'acat1 dans le traitement de maladies neurodégénératives
EP4066859A1 (fr) * 2014-08-08 2022-10-05 Alector LLC Anticorps anti-trem2 et leurs procédés d'utilisation
CA2990578C (fr) 2015-06-30 2023-09-26 National University Corporation Okayama University Medicament pour la prevention ou le traitement d'une maladie inflammatoire de l'intestin
WO2017058866A1 (fr) 2015-09-28 2017-04-06 Precision Immune, Inc. Anticorps anti-trem2 et leurs utilisations
JP2018537956A (ja) * 2015-10-06 2018-12-27 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
US20180318241A1 (en) 2015-10-31 2018-11-08 Io Therapeutics, Inc. Treatment of nervous system disorders using thyroid hormone neutral doses of rxr agonists
WO2018134815A2 (fr) * 2017-01-17 2018-07-26 Yeda Research And Development Co. Ltd. Procédés de traitement de maladies neurodégénératives par induction de cellules de microglie associées à une maladie (dam)
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
TW202342547A (zh) 2017-08-03 2023-11-01 美商阿列克特有限責任公司 抗trem2抗體及其使用方法
CA3083660A1 (fr) 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anticorps anti-trem2 et methodes associees

Also Published As

Publication number Publication date
EP3887401A2 (fr) 2021-10-06
WO2020112889A9 (fr) 2021-06-10
JP2022513114A (ja) 2022-02-07
CN113302206A (zh) 2021-08-24
US20230132366A9 (en) 2023-04-27
US20220025039A1 (en) 2022-01-27
WO2020112889A3 (fr) 2020-07-30
CA3120970A1 (fr) 2020-06-04
WO2020112889A2 (fr) 2020-06-04

Similar Documents

Publication Publication Date Title
MA54296A (fr) Procédés de traitement du métabolisme lipidique dérégulé
MA50056A (fr) Procédés de traitement de tumeur
MA47613A (fr) Compositions et procédés de traitement du cancer
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA53506A (fr) Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
MA50569A (fr) Ensembles de remplissage-finition et procédés associés
MA56212A (fr) Compositions et méthodes de traitement du cancer
MA45488A (fr) Procédés, kits et appareil de culture de cellules
MA51306A (fr) Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
MA52962A (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
MA52789A (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
MA55087A (fr) Compositions et procédés de traitement de laminopathies
MA52216A (fr) Méthodes de traitement de la colite ulcéreuse
MA47172A (fr) Compositions et procédés de traitement des inflammations intestinales et du cancer du côlon
MA42974A (fr) Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer
MA46361A (fr) Traitement du cancer de la prostate
MA47408A (fr) Traitement du cancer
MA45489A (fr) Procédés de culture de cellules, kits et appareil associés
MA46061A (fr) Traitement ascaroside de maladies auto-immunes et inflammatoires
MA43867A (fr) Appareil de mélange et de traitement et méthode
MA53741A (fr) Procédés de traitement de troubles myéloprolifératifs
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie